Intermittent minodronic acid treatment with sufficient bone resorption inhibition prevents reduction in bone mass and strength in ovariectomized rats with established osteopenia comparable with daily treatment

Bone

Volumn 55, Issue 1, 2013, Pages 189-197

  Kimoto, Aishi ^a   Tanaka, Makoto ^b   Nozaki, Kazutoshi ^a   Mori, Masamichi ^a   Fukushima, Shinji ^a   Mori, Hiroshi ^b   Shiroya, Tsutomu ^b   Nakamura, Toshitaka ^c  

^a ASTELLAS PHARMA INC   (Japan)

^b ONO PHARMACEUTICAL CO   (Japan)

^c UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Bisphosphonate; Histomorphometry; Minodronic acid; Osteoporosis; OVX

Indexed keywords

DEOXYPYRIDINOLINE; MINODRONIC ACID; OSTEOCALCIN; PLACEBO;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BLOOD ANALYSIS; BONE DENSITY; BONE MASS; BONE STRENGTH; BONE STRUCTURE; BONE TURNOVER; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG TISSUE LEVEL; DUAL ENERGY X RAY ABSORPTIOMETRY; EX VIVO STUDY; EXPERIMENTAL RAT; FEMALE; FEMUR; LOW DRUG DOSE; LUMBAR VERTEBRA; MORPHOMETRICS; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; OVARIECTOMY; RAT; TRABECULAR BONE; TREATMENT DURATION; URINALYSIS; VERTEBRA BODY;

ANIMALS; BIOLOGICAL MARKERS; BIOMECHANICAL PHENOMENA; BONE AND BONES; BONE DENSITY; BONE DISEASES, METABOLIC; BONE RESORPTION; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FEMUR; IMIDAZOLES; LUMBAR VERTEBRAE; ORGAN SIZE; OVARIECTOMY; RATS; RATS, INBRED F344; WEIGHT-BEARING;

EID: 84877589737     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2013.02.013     Document Type: Article

References (31)

1. Teitelbaum S.L. Bone resorption by osteoclasts. Science 2000, 289:1504-1508.
2. Marcus R., Majumder S. The nature of osteoporosis. Osteoporosis 2001, 3. Academic Press, London. R. Marcus, D. Feldman, J. Kelsey (Eds.).
3. Cummings S.R., Melton L.J. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002, 359:1761-1767.
4. Seeman E. Pathogenesis of bone fragility in women and men. Lancet 2002, 359:1841-1850.
5. Delmas P.D. Treatment of postmenopausal osteoporosis. Lancet 2002, 359:2018-2026.
6. World Health Organization Guidelines for the preclinical evaluation and clinical trials in osteoporosis 1998, WHO, Geneva.
7. Liberman U.A., Weiss S.R., Bröll J., Minne H.W., Quan H., Bell N.H., et al. Effect of three years' treatment with oral alendronate on bone mineral density and fracture incidence in women with postmenopausal osteoporosis. N Engl J Med 1995, 333:1437-1443.
8. Black D.M., Cummings S.R., Karpf D.B., Cauley J.A., Thompson D.E., Nevitt M.C., et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996, 348:1535-1541.
9. Adachi J.D., Bensen W.G., Brown J., Hanley D., Hodsman A., Josse R., et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997, 337:382-387.
10. Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med 1998, 338:736-746.
11. Dunford J.E., Thompson K., Coxon F.P., Luckman S.P., Hahn F.M., Poulter C.D., et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001, 296:235-242.
12. Takeuchi M., Sakamoto S., Kawamuki K., Kurihara H., Nakahara H., Isomura Y. Studies on novel bone resorption inhibitors. II. Synthesis and pharmacological activities of fused aza-heteroarylbisphosphonate derivatives. Chem Pharm Bull 1998, 46:1703-1709.
13. Harris S.T., Watts N.B., Genant H.K., McKeever C.D., Hangartner T., Keller M., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. J Am Med Assoc 1999, 282:1344-1352.
14. Seedor J.G., Quartuccio H.A., Thompson D.D. The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats. J Bone Miner Res 1991, 6:339-346.
15. Matsumoto T., Hagino H., Shiraki M., Fukunaga M., Nakano T., Takaoka K., et al. Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study. Osteoporos Int 2009, 20:1429-1437.
16. Cotte F.E., Fardellone P., Mercier F., Gaudin A.F., Roux C. Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int 2010, 21:145-155.
17. Tanaka M., Mori H., Kayasuga R., Ochi Y., Kawada N., Yamada H., et al. Long-term minodronic acid (ONO-5920/YM529) treatment suppresses increased bone turnover, plus prevents reduction in bone mass and bone strength in ovariectomized rats with established osteopenia. Bone 2008, 43:894-900.
18. Usui T., Kamimura H. Pharmacokinetics of minodronic acid hydrate, a novel bisphosphonate, in rats and dogs. Clin Pharmacol Ther 2008, 18:S129-S142.
19. Parfitt A.M., Drezner, Glorieux F.H., Kanis J.A., Malluche H., Meunier P.J., et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Miner. Res. 1987, 2:595-610.
20. Usui T., Kawakami R., Watanabe T., Higuchi S. Sensitive determination of a novel bisphosphonate, YM529, in plasma, urine and bone by high-performance liquid chromatography with fluorescence detection. J Chromatogr 1994, 652:67-72.
21. Wronski T.J., Cintron M., Dann L.M. Temporal relationship between bone loss and increased bone turnover in ovariectomized rats. Calcif Tissue Int 1988, 43:179-183.
22. Chesnut C.H., Skag A., Christiansen C., Recker R., Stakkestad J.A., Hoiseth A., et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004, 19:1241-1249.
23. Rossini M., Gatti D., Girardello S., Braga V., James G. Effects of two intermittent alendronate regimens in the prevention or treatment of postmenopausal osteoporosis. Bone 2000, 27:119-122.
24. Ebetino F.H., Hogan A.M., Sun S., Tsoumpra M.K., Duan X., Triffitt J.T., et al. The relationship between the chemistry and biological activity of the bisphosphonates. Bone 2011, 49:20-33.
25. Russell R.G., Watts N.B., Ebetino F.H., Rogers M.J. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008, 19:733-759.
26. Fratzl P., Gupta H.S., Paschalis E.P., Roschger P. Structure and mechanical quality of the collagen-mineral nano-composite in bone. J Mater Chem 2004, 14:2115-2123.
27. Seeman E., Delmas P.D. Bone quality - the material and structural basis of bone strength and fragility. N Engl J Med 2006, 354:2250-2261.
28. Wimalawansa S.J. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. Am J Med 1998, 104:219-226.
29. Package inserts of RECALBON® (Ono Pharmaceutical Co., Ltd.) and Bonoteo® (Astellas Pharma Inc.); 2011.
30. Chapurlat R.D., Delmas P.D. Drug insight: bisphosphonates for postmenopausal osteoporosis. Nat Clin Pract Endocrinol Metab 2006, 2:211-219.
31. Okazaki R., Hagino H., Ito M., Sone T., Nakamura T., Mizunuma H., et al. Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis. Osteoporos Int 2012, 23(6):1737-1745.